

ESPS Peer-review Report

Name of Journal: World Journal of Hepatology

ESPS Manuscript NO: 5430

Title: HBV antibody courses and HBV reactivation with rituximab

Reviewer code: 01800499

Science editor: Cui, Xue-Mei

Date sent for review: 2013-09-11 14:47

Date reviewed: 2013-09-16 01:05

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

Confusing paper, I am not sure it was written to be clinical practice / review or case series. Also, next time, have native English speakers check language.

ESPS Peer-review Report

Name of Journal: World Journal of Hepatology

ESPS Manuscript NO: 5430

Title: HBV antibody courses and HBV reactivation with rituximab

Reviewer code: 00148365

Science editor: Cui, Xue-Mei

Date sent for review: 2013-09-11 14:47

Date reviewed: 2013-09-20 00:06

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

GENERAL COMMENTS MAJOR POINTS This is a comprehensive review on HBV reactivation in patients treated with rituximab for malignant and non-malignant diseases. The review is well written, the significance of the content is adequate, although no novelty is provided. The presentation should be improved by adding a table (see specific comments). Only minor comments are addressed.

SPECIFIC COMMENTS 1. Title: it should be improved, being more adequate to the contents of the study. 2. Abstract: The authors mention 'thrombocytopenic purpura'. Do they mean thrombotic thrombocytopenic purpura? 3. HBV reactivation following rituximab treatment. CTL should be defined. 4. Anti HBs-positive, Anti HBc-positive and HBsAg negative cases. What does THP mean? 5. Nucleoside analog treatment for the prevention of HBV reactivation. The doses of adefovir, telbivudine and tenofovir should be included 6. Figure legend. Should be improved 7. Table legend. Should be included 8. A table with the summary of the recommendations for prevention of HBV reactivation in the situations discussed in the article should be included in order to check rapidly the most essential actions to be taken.

ESPS Peer-review Report

Name of Journal: World Journal of Hepatology

ESPS Manuscript NO: 5430

Title: HBV antibody courses and HBV reactivation with rituximab

Reviewer code: 00068903

Science editor: Cui, Xue-Mei

Date sent for review: 2013-09-11 14:47

Date reviewed: 2013-09-27 19:09

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This is a comprehensive and well-structured review on HBV reactivation under rituximab therapy. It starts with current knowledge on HBV reactivation in general. It then covers risk factors and various patient groups according to their serologic status, before finishing with preventive treatment options. This manuscript would benefit from a language editing. Thus, most of my only minor points regard language: 1. Different from cells, viruses do not proliferate, they replicate. Please change that term, e.g. page 2, conclusions 2. page 3 line 6 from the bottom ‘..effort to identify patient.’ ? 3. page 6 main para 2nd sentence ‘While it is generally believed...’: This is misleading. Why should it be generally believed that an anti-HBc-positive case should be due to vaccination? 3. page 6 line 17 from the bottom ‘.. a patient in whom ...’. 4. page 6 line 8 from the bottom ‘titer levels’, better use either ‘titers’ or ‘levels’. 5. page 10 conclusion lines 9/10, is reconstitution meant?